Criteria for definition of “failure” based on European LeukemiaNet recommendations (2006)27 and criteria for “optimal response” based on European LeukemiaNet recommendations (2009). The criteria are based on the assumption that a patient with chronic myeloid leukemia (CML) in early chronic phase (ECP) starts imatinib at 400 mg daily. The revised European LeukemiaNet recommendations (2009) are now in press (Baccarani et al. J Clin Oncol. In press).
| . | Failure (2006) . | Optimal response (2009) . |
|---|---|---|
| CHR indicates complete hematologic response; CyR, cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response. | ||
| 3 months | No hematologic response | CHR, and at least a minor CyR (Ph+ < 65%) |
| 6 months | Less than CHR No CyR (Ph+ > 95%) | At least a partial CyR (Ph+ < 35%) |
| 12 months | Less than partial CyR | CCyR (Ph+ > 35%) |
| 18 months | Less than CCyR | MMR (3-log reduction in transcripts) |
| Any time | Loss of CHR, loss of CCyR, kinase domain mutation, insensitive to imatinib | |
| . | Failure (2006) . | Optimal response (2009) . |
|---|---|---|
| CHR indicates complete hematologic response; CyR, cytogenetic response; CCyR, complete cytogenetic response; MMR, major molecular response. | ||
| 3 months | No hematologic response | CHR, and at least a minor CyR (Ph+ < 65%) |
| 6 months | Less than CHR No CyR (Ph+ > 95%) | At least a partial CyR (Ph+ < 35%) |
| 12 months | Less than partial CyR | CCyR (Ph+ > 35%) |
| 18 months | Less than CCyR | MMR (3-log reduction in transcripts) |
| Any time | Loss of CHR, loss of CCyR, kinase domain mutation, insensitive to imatinib | |